Coave Therapeutics: redecorating viral vectors for improved gene therapies Coave Therapeutics is a French biotech developing gene therapies for neurodegenerative and ocular diseases. The company has developed a technology […] January 25, 2023 · V-Bio Ventures
The inspiring potential of gene therapy in neurology Dr. Monica Bennett is Head of Gene Therapy Unit at Novartis, the company behind the world’s only gene therapy approved […] September 7, 2022 · BioVox
V-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain […] August 31, 2022 · V-Bio Ventures
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio Ventures
Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints […] May 10, 2022 · Turnstone Communications
Abscint labels antibodies with radioactive material to spot harmful cells Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies […] March 16, 2022 · BioVox
V-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio Ghent, Belgium, 1 March 2022 – V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi […] March 1, 2022 · V-Bio Ventures
Confo-dently into the future! Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, […] November 24, 2021 · V-Bio Ventures
Biogen’s controversial Alzheimer’s drug approved by the FDA – what now? It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug […] September 22, 2021 · V-Bio Ventures
Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy – Newton together with public and private investment partners invests in NeuVasQ for the development of blood-brain barrier pharmaceuticals based […] June 22, 2021 · Turnstone Communications
To fund or not to fund: the psychology of investment decisions Much has been written about the psychology of decision making and how venture capitalists choose which companies they want to […] April 28, 2021 · V-Bio Ventures
Augustine Therapeutics developing new medicines for neuromuscular diseases Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened […] March 31, 2021 · Turnstone Communications
Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases Leuven, Belgium, 23 March 2021 – Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of […] March 23, 2021 · Turnstone Communications
Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board Leuven, Belgium, 19th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 19, 2021 · Turnstone Communications
Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases Leuven, Belgium, 18th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 18, 2021 · Turnstone Communications